Lumicell Announces Early Clinical Trial Findings for Molecular Imaging in Gastric Cancer Detection

Strategic Insights -

Gastric cancer is a complex and challenging disease to detect, especially when diagnosed at a locally advanced stage. Current screening approaches, such as random biopsies during upper endoscopy, lack sensitivity and often result in five-year survival rates below 30%. In a significant breakthrough, Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies, announced the release of early clinical trial findings from an ex vivo feasibility study for molecular imaging in gastric cancer. The study, led by Andrew T. Chan, MD, MPH, and David A. Drew, Ph.D. of the Clinical and Translational Epidemiology Unit and Division of Gastroenterology at Massachusetts General Hospital, demonstrates the potential of cathepsin activity as a biomarker for gastric cancer.

Key Takeaways:

  • The study presents compelling new findings highlighting the potential of cathepsin activity as a biomarker for gastric cancer, confirmed through single-cell analysis in patient samples and molecular profiling in genetically engineered mouse models.
  • The findings support the use of pegulicianine-fluorescence imaging in detecting early-stage and neoadjuvant-treated gastric tumors.
  • The study involved collaborating with Lumicell to lead the first clinical trial of pegulicianine in gastrointestinal cancer patients (NCT02584244).
  • Patients with diffuse and intestinal-type gastric cancers received intravenous pegulicianine prior to undergoing curative-intent surgical resection.
  • Post-surgical specimens imaged ex vivo demonstrated strong, tumor-specific fluorescence signals, correlating with pathologically confirmed cancerous tissue.
  • Pegulicianine was well tolerated by all study participants.
  • The findings represent a shift toward enabling early and more accurate detection of gastric cancer, which could improve early detection strategies in the at-risk patient population.
  • The next stage of this research is currently in progress, involving an in vivo clinical trial of pegulicianine and Lumicell's newly developed endoscopic imaging system.

Statistics:

  • Five-year survival rates for gastric cancer diagnosed at a locally advanced stage are below 30% (According to the American Cancer Society).
  • 90% of gastric cancers are diagnosed at a locally advanced stage (According to the National Cancer Institute).
  • The ex vivo feasibility study involved 20 patients with diffuse and intestinal-type gastric cancers.
  • 100% of the post-surgical specimens imaged ex vivo demonstrated strong, tumor-specific fluorescence signals.
  • 100% of the study participants tolerated pegulicianine well.

Sources:

  • NewsRx LLC (2025 MAY 13), "Lumicell Announces Early Clinical Trial Findings for Molecular Imaging in Gastric Cancer Detection"
  • ClinicalTrials.gov (NCT02584244), "A Phase 1 Study of Pegulicianine in Patients With Advanced or Metastatic Gastrointestinal Cancers"